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Abstract 
Alchemix is an exemplar of a class of anthraquinone with efficacy against multidrug resistant 
tumors. We have explored further the mechanism of action of alchemix and investigated the 
effect of extending its side arm bearing the alkylating functionality with regard to DNA 
binding and activity against multidrug resistant cancer cells. Increasing the distance between 
the intercalating chromophore and the alkylating functionality of ICT2901 (propyl), ICT2902 
(butyl) and ICT2903 (pentyl), led to a higher number of DNA alkylation sites, more potent 
topoisomerase II inhibition and generated more apoptotic and necrotic cells when analysed in 
p53-proficient HCT116 cells. Intriguingly, alchemix, the compound with the shortest distance 
between its intercalative chromophore and alkylating functionality (ethyl), did not conform to 
this SAR. A different toxicity pattern against DNA repair defective CHO cell lines as well as 
arrest of cells in G1 supports a somewhat distinct mode of action by alchemix compared with 
its analogues. Importantly, both alchemix and ICT2901 demonstrated greater cytotoxic 
activity against anthraquinone-resistant MCF-7/adr cells than wild-type MCF-7 cells. Subtle 
synthetic modification in this anthraquinone series has led to significant changes to the 
stability of DNA-compound complexes and cellular activity. Given that the failure of 
chemotherapy in the clinic is often associated with MDR, the results of both alchemix and 
ICT2901 represent important advances towards improved therapies.  
 
 
Keywords: anthraquinone, H2AX phosphorylation, MDR, topoisomerase II, NER, p53. 
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Abbreviations  
CHO  Chinese Hamster Ovary 
CT DNA Calf thymus DNA 
DMSO  Dimethyl sulphoxide 
DSB  Double strand break 
H2AX  Histone-2AX 
MDR  Multidrug resistance 
MTT  (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
TdT  Terminal deoxynucleotidyl transferase 
Topo II Topoisomerase II 
TUNEL Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling 
SAR  Structure-activity relationship 
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1. Introduction 
Topoisomerase II (topo II) inhibitors are often based on planar aromatic pharmacophores, 
which constitute an important class of clinically useful anti-tumor agent. Daunorubicin, 
doxorubicin, epirubicin and mitoxantrone are established drugs that are based on a tricyclic 
anthraquinone pharmacophore, which is a prerequisite for topo II poisoning [1]. Substantial 
work has defined the relationship between the basic aminoalkylamino sidechains and 
configuration of functional groups attached to the 1,4-disubstituted pharmacophore of 
mitoxantrone [1-7]. The clinical success of the anthraquinone-based anticancer drugs is 
tempered by their failure in tumors that express the ABCB1 (MDR1) gene [8-10], or exhibit 
downregulation/mutation [11] or phosphorylation [12] of topo II. In an attempt to overcome 
these resistance mechanisms, we have previously reported 1,4-disubstituted 
chloroethylaminoanthraquinones as a hybrid class of agents containing DNA intercalating and 
alkylating functionalities [13, 14], of which one agent, alchemix (Figure 1) possesses 
substantial anticancer activity against doxorubicin- (A2780AD) and cisplatin-resistant 
(A2780/cp70) tumor xenografts in mice [15]. In particular, symmetrical (two identical 
sidechains) 1,4-disubstituted anthraquinones with alkylating groups on both sidechains lose 
cytotoxic potency in multidrug-resistant (MDR) cancer cells, but non-symmetrical mixed 
sidechain-configured anthraquinones, typified by alchemix, remain effective against such 
malignant cells [14, 15].  
 
 
Figure 1 
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 This study expands the knowledge of the DNA binding properties of alchemix and its 
cellular pharmacology. To explore these phenomena, three novel analogues of alchemix were 
prepared (Figure 1), which would provide a platform for a better understanding of the 
optimum requirements for DNA adduct formation, topo IIα inhibition and cytotoxicity.  
 
2. Materials and methods 
 
2.1. Synthesis of target compounds 
The synthesis of alchemix and the three novel anthraquinones was carried out using 
methodology previously reported [13]. Briefly, ipso-substitution of 1-(2-
(dimethylamino)ethylamino)-4-fluoro-5,8-dihydroxyanthracene-9,10-dione with the 
respective bis(hydroxyl)-aminoalkylamine generated bis-substituted hydroxyethyl precursors, 
which were converted to the target chloro compounds using triphenylphosphine-carbon 
tetrachloride complex (PPh3-CCl4). Full experimental methodology and characterisation of 
ICT2901, ICT2902 and ICT2903 can be found in supporting information. All compounds 
were stored as hydrochloride salts at –20 °C under anhydrous conditions prior to use. 
 
2.2. DNA binding studies 
Doxorubicin, mechlorethamine (N-methyl-N,N-bis(2-chloroethyl)amine), 3-(4,5-simethyl- 2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), ammonium persulphate (APS), and 
sequagel 6 (concentrate) were obtained from Sigma-Aldrich Chemicals (Gillingham, U.K.). 
Plasmid DNA pBR322 (0.25 U/µL) was purchased from New England Biolabs (Herts, U.K.), 
γ32P-ATP (500 Ci/mmol), 5´-TATGCGACTCCTGCATTAGG-3´ primer (10 pm/µl), dNTP 
mix (2.5 mM), T4 polynucleotide kinase (5 U/µl), bacterial alkaline phosphatase (BAP) (150 
U/µl), Taq DNA polymerase (5 U/µl) and Hind III (15 U/µl), BamH1 and SalI restriction 
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enzymes were purchased from Promega, (Southampton, UK). BIO-RAD spin columns were 
obtained from BIO-RAD Laboratories, (Beckenham, UK).  
 
 2.2.1. Taq polymerase stop assay 
This experiment has previously been described [13, 16]. Briefly, the following constituents 
were added to a PCR tube: 0.2 % gelatine (5 µl), 25 mM MgCl2 (10 µl), 10 × Taq polymerase 
buffer buffer (10 µl), 2.5 mM dNTP mix (10 µl), dH2O (8 µl) and 0.5µg drug-treated (1-100 
nM) linearised pBR322 DNA (50 µl). The latter was generated after incubation for 1 h at 37 
°C. To the mixture (93 µl) was then added a synthetic 20 base oligonucleotide primer that 
binds to the sequence 621-640 of the 273 base pair BamH I/Sal I fragment of pBR322 (bases 
375-650), Taq polymerase (2 µL, 5 U/µl), and the final mixture was vortexed. The 
thermocycler was programmed to: (1) 95 °C for 5 min, (2) 95 °C for 1 min, (3) 58 °C for 1 
min, (4) 74 °C for 1 min and an additional 1 min per cycle. Step 2–4 were repeated 29 times 
before denaturing at 94 °C for 5 min followed by 10 min at 25 °C. The samples were then 
transferred into sterile eppendorf vials and the DNA precipitated with 3 volumes of ethanol 
(95 %, 300 µl) and NaOAc (3 M, 2 µl), vortexed and cooled in dry ice bath for 10 min before 
being centrifuged at 13,000 rpm for 10 min. The supernatant was removed and the samples 
were washed with ethanol (70 %, 150 µl), vortexed, centrifuged at 13,000 rpm for 10 min and 
the supernatant removed. The wash was repeated and the samples lyophilized. Each dried 
sample was re-suspended in formamide dye (4 µl), heated to 95 °C for 3 min and cooled in an 
ice-bath to denature the DNA. The samples were loaded into the wells of a 6% denaturing 
polyacrylamide gel and electrophoresis was performed in TBE buffer at 1600-2000 V 
(approx. 2–3 h, 55 °C) using vertical glass electrophoresis plates. The resulting gel was then 
transferred onto a Whatman 3MM filter paper and one layer of DE81, covered in film wrap 
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and dried on a BIO-RAD 583 gel drier for approximately two h. Once dry, the gel was 
exposed to a Kodak Hyperfilm for 24 h before development.  
 
2.2.2. UV thermal melting studies of ligands and calf thymus DNA 
The protocol used to determine thermal denaturation profiles for double-stranded calf thymus 
(CT) DNA and ligand-induced melting temperature shifts (∆Tm) has been previously 
described [17, 18]. CT DNA (sodium salt) was purchased from Sigma and used without 
further purification; the buffer used was aqueous sodium phosphate (Na2HPO4/NaH2PO4 10 
mM, Na2EDTA 1 mM, pH 7.00), CT DNA solutions were quantitated spectrophotometrically 
using ε260 = 12 824 M(base pairs)-1 cm-1 at 260 nm. Anthraquinones were dissolved in DMSO 
and stock solutions stored at 4 °C. Ligand-DNA mixtures were prepared by carefully adding 
ligand stock solution to DNA to achieve a final concentration of 50 µM (bp) DNA and 10 µM 
anthraquinone, ensuring that the final concentration of DMSO was < 1% v/v. DMSO 
calibration curves were used to correct the Tm values. 
 UV DNA melting curves were determined using a Varian-Cary 400 Bio UV/vis 
spectrophotometer equipped with a Peltier temperature controller. Heating was applied at a 
rate of 1 °C/min in the range 40–95 °C, the absorbance was monitored continuously at 260 
nm. All melts were performed in 1 cm path length, masked quartz cells. For kinetic 
experiments, working solutions of DNA-anthraquinone mixtures at the fixed 5:1 molar ratio 
were incubated at 37 °C and evaluated at set time points of 0, 4, 8 and 24 h. Results for each 
compound are means of three separate determinations. 
 
2.3. Topoisomerase II decatenation assay  
Decatenation of kinetoplast DNA (kDNA; from Crithidia Fasciculata and purchased from 
TopoGEN) was used to assay the level of topo IIα inhibition. The standard topo IIα 
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(purchased from affymetrix/USB) reaction mixture contained 10 mM Tris-HCl, pH 7.9, 175 
mM KCl, 5 mM MgCl2, 0.1 mM EDTA, 0.2 mM dithiothreitol, 2.5% glycerol, 1 mM ATP, 
30 µg/ml BSA, 0.1 µg kDNA and sterile distilled water to 20 µl. The reaction was incubated 
with 4U of topo IIα at 37 °C for 30 min and terminated by the addition of 5 µl of stop buffer 
(10% w/v sodium dodecyl sulphate, 50% glycerol, 0.025% bromophenol blue).  The reaction 
mixture was centrifuged at 14000 g for 10 sec. The blue mixture was loaded directly onto 1% 
horizontal agarose gel and electrophoresed in 90 mM Tris-base, pH 8.3, 2.5 mM EDTA. Gels 
were electrophoresed for 4 h at 6 V/cm and photographed under UV transillumination for 30 
sec. 
 
2.4. Chemosensitivity 
All drugs were dissolved in DMSO to obtain stock solutions at 10 mM, aliquoted and stored 
at –20 oC prior to use. MCF-7, MCF-7/adr, HCT116p53+/+ and HCT116p53-/- cancer cell lines 
(obtained from ATCC) were routinely maintained as mono-layered cultures in RPMI 1640 
medium supplemented with 10 % fetal bovine serum, 2 mM L-glutamine and 1 mM sodium 
pyruvate. The arrest of cell growth was determined by the MTT assay as previously reported 
[19]. Briefly, cells were plated in 96-well plates with 200 µl of cell suspension (0.5×104 
cell/ml) per well. Cells were left to adhere overnight at 37 °C in a humidified incubator (5% 
CO2 and 95% air) and then exposed to a suitable range of drug concentrations for 1 h or 96 h 
in complete RPMI 1640 medium. Following drug exposure, cells were washed three times 
with Hanks Balanced Salt Solution and complete growth medium (200 µl/well) was added. 
Chemosensitivity was determined using the MTT assay 4 days later. For both 1 h and 
continuous drug exposures, MTT (20 µl, 5mg/ml) was added to each well and the plates 
incubated at 37 °C for 4 h. All medium was removed and formazan crystals were dissolved in 
150 µl of DMSO. The absorbance of the resulting solution was measured at 540 nm using a 
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multiwell spectrophotometer (Multiskan EX; Thermo Fisher Scientific, Waltham, MA, USA). 
Survival and chemosensitivity were expressed as IC50 values. All experiments were repeated 
in triplicate.  
 
 2.5. γH2AX and cell cycle analysis 
HCT116p53+/+ colorectal carcinoma cells were exposed to drug concentrations equal to the 
IC80 value for a 1 h drug exposure followed by removal of the drug and recovery in fresh 
medium for 3, 24 or 48 h. Cells were collected by trypsinization and fixed in ice-cold 
methanol at –20 °C for 30 min. Cells were collected by centrifugation and washed in PBS. 
Following inhibition of non-specific antibody binding by incubation in staining buffer (5% 
BSA in PBS) for 10 min at room temperature, cells were incubated for 60 min at room 
temperature with anti-phospho-histone H2AX antibody, Ser 139, (Cell Signaling Technology, 
USA; diluted 1:50 in staining buffer). Cells were washed in staining buffer and 
immunoreactivity was detected using an anti-rabbit Alexa Fluor®-488 labeled secondary 
antibody (Cell Signaling Technology, USA; diluted 1:1000). Cells were further washed in 
staining buffer and resuspended in PBS containing propidium iodide (200 µg/ml; Sigma, 
Gillingham, UK) and RNase A (200 µg/ml; Invitrogen, Paisley, UK) at 37 °C for 30 min. 
Vials were placed on ice before analysis. Flow cytometry analyses were performed using a 
FACS-Calibur flow cytometer (BD Biosciences; San Jose, CA, USA). Data obtained from 
10,000 cellular events were analyzed using the CellQuest software (BD Biosciences; San 
Jose, CA, USA). 
 
2.6. Induction of cellular apoptosis and necrosis 
HCT116p53+/+ colorectal carcinoma cells were exposed to drug concentrations equal to the 
IC80 value for 1 h, followed by removal of the drug and recovery in fresh medium for 24 h. 
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Cells were collected by trypsinization and resuspended in PBS. Cell suspensions (100 µl) 
were applied to poly-L-lysine coated microscope slides and air-dried in a fume hood at room 
temperature. Slides were incubated in buffered formalin for 5 min at room temperature to fix 
cells and then washed twice with PBS. Apoptotic cells were detected using the DeadEnd 
Colorimetric TUNEL assay (Promega, USA) according to the manufacturer’s instructions. At 
least 500 cells were counted per slide from 10 random areas and the resultant percentage of 
apoptotic cells determined.  
 For determination of necrosis, cell suspensions were mixed with equal volumes of 
Trypan Blue solution (0.4%, Sigma). The percentage of necrotic cells was then calculated by 
counting the proportion of blue versus unstained cells using a haemocytometer. All results are 
the mean of three independent experiments. 
 
2.7. Studies in Chinese Hamster Ovary (CHO) cell lines 
1 x104 CHO cells were seeded in a 96-well plate in 200 µl DMEM. After 24 h the cells were 
treated with indicated compounds for 120h. After treatments, the wells were rinsed twice with 
HBSS++ (200 µl/well) before fixation for 20 min in 4% formaldehyde/1% CaCl2, twice rinsing 
with distilled water before staining with 0.01% neutral red (NR) in water for 1 h. The plates 
were rinsed an additional three times in water followed by addition of 200 µl 1% acetic 
acid/50% ethanol added to each well for incubation for 30 min. Finally, absorbance was 
measured at 540 nm and data analysed as previously described [20]. 
 
3. Results 
3.1. DNA sequence-selective alkylation and inter-strand cross-linking experiments 
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Compounds ICT2901, ICT2902 and ICT2903 were compared with alchemix for their ability 
to covalently adduct double-stranded DNA using the Taq polymerase stop assay [16]. 
Inhibition of DNA elongation, consistent with DNA alkylation, was detected down to 5 nM 
for ICT2902 and ICT2903 compared with 1 µM for mechlorethamine (Figure 2). The four 
alkylating anthraquinones demonstrated a strong preference for guanines, specifically the 
guanines that were flanked by a 5’-cytosine and a 3’-guanine residue (e.g. 5'-CGG; positions 
536, 586 and 596 in Figure 2) and to a lesser extent at the second guanine in the same 
sequence (5'-CGG; positions 537, 587 and 597). A potentially important alkylation site was 
also observed at position 529 in the sequence 5'-CGT, which was not an alkylation site shared 
by mechlorethamine. In contrast, mechlorethamine showed a pattern of sequence selective 
alkylation as observed previously, with a preference for reaction within runs of contiguous 
guanines [21]. For example, alkylation was observed at 5'-TGGGC, which was not a target 
site for any of the four anthraquinones, suggesting that the 5'-TG or 5'-GG residue is not an 
ideal site for DNA intercalation to occur. Alkylation was observed, however, with all 
compounds at the guanine-rich sequence 5'-CGGGGG (bases 536-540) with the 
anthraquinones preferring alkylation of Gs at the 5' terminus of the G-tract and 
mechlorethamine the middle Gs. There was no apparent difference in sequence selectivity 
between alchemix and the three novel compounds ICT2901, ICT2902, and ICT2903 although 
qualitative differences in reactivity were evident. For example, compounds ICT2902 and 
ICT2903 with butyl (n = 3) or pentyl (n = 4) linkers respectively, revealed more intense bands 
at several alkylation sites including at base positions 536-540. None of the four agents was 
shown to cause DNA interstrand crosslinking in concentration-dependent (0.1–100 nM) 
experiments using a gel-based electrophoretic assay (Figure S1, Supporting Information).  
 
 
Figure 2 
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3.2. DNA thermal denaturation studies 
Reactivity of the four anthraquinones towards double-stranded DNA was assessed by 
measuring their capacity to modify the melting behavior (Tm) of calf thymus DNA. Using a 
5:1 (50 µM DNA:10 µM compound) ratio and analysis of the “instant” (t = 0) DNA binding, 
the compounds were found to shift the DNA melting curve moderately (∆Tm = 6.5-14.8˚C) 
(Table 1). Interestingly, notable differences in their DNA binding mode became apparent 
when studying time-dependent incubations at 37 °C for up to 24 h. Alchemix (n = 1) and 
ICT2901 (n = 2) exhibited the most stable interactions with DNA; the ∆Tm observed at t = 0 
(11.0 and 14.8 °C, respectively) decreased only slightly after  24 h. In contrast, ICT2902 (n = 
3) and ICT2903 (n = 4), compounds with the longer carbon sidechains, were less effective in 
stabilizing the DNA duplex at the onset of the experiment (∆Tm ≤ 7 °C) but over the course of 
24 h incubation,  ∆Tm decreased in a near-linear fashion to zero (supporting information, 
Figure S2).  
 
Table 1 
 
 
 
3.3. Inhibition of topo IIα activity 
The ability of the four compounds to inhibit topo IIα was measured using catenated 
kinetoplast DNA. The experiments was carried out as previously described using the 
anthraquinone-based clinical prodrug AQ4N and its metabolite AQ4 (topo IIα inhibitor) as 
negative and positive controls respectively [22]. All compounds were shown to completely 
inhibit topo IIα at 2.5 µM but at lower concentrations a dose-response was observed. Figure 3 
shows that both ICT2902 and ICT2903 prevent the catenated kinetoplast DNA in migrating at 
100 nM indicative of topo II inhibition. In contrast, alchemix is not able to inhibit the 
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formation of individual DNA circles and intermediate-sized catenated complexes whereas 
ICT2901 partly prevents decatenation.  
 
 
Figure 3 
 
 
 
3.4. Chemosensitivity 
The response of cell lines to alchemix and its analogues are presented in Tables 2 and 3. 
Following a 1 h exposure, all four compounds showed comparative activity against p53 
proficient and deficient HCT116 cell lines with resistance factors (RF, the ratio of IC50 values 
in p53-/- cells to p53+/+ cells) ranging from 1.13 to 1.65 (Table 2). Similar results were 
obtained following a 96 h drug exposure although RF values increased modestly (1.59 to 
3.26, Table 2). Of the four compounds evaluated, ICT2901 was the most potent following 
both a 1 and 96 h exposure against all cell lines evaluated (Tables 2 and 3). Potency generally 
decreased as the length of the side chain increased with the exception of alchemix where IC50 
values typically fell within the range of IC50 values observed. Against the MCF-7 and MCF-
7/adr cells, alchemix and ICT2901 were preferentially active against MCF-7/adr cells (Table 
3). This contrast sharply with doxorubicin, which was significantly (> 45 fold) less active 
against MCF-7/adr cells (Table 3). ICT2902 was equitoxic against both cell lines whereas 
ICT2903 was less active against MCF-7/adr cells. Comparing the activity of all 
anthraquinones against cells following a 1 h and 96 h exposure, it is clear that differences in 
IC50 values are small in all cases. This is in marked contrast to doxorubicin where the IC50 
values against MCF-7 cells are 218 ± 91 and 6.1 ± 2 µM for 96 and 1 h exposures 
respectively (Table 3). 
 
 
Table 2 
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Table 3 
 
 
 
3.5. Cell Cycle 
The effect on cell cycle progression was investigated by flow cytometry in the HCT116p53+/+ 
cell line exposed to IC80 drug concentrations for 1 h. Analysis of cell cycle progression was 
subsequently performed at time points 0, 3, 24 and 48 h after recovery in drug-free medium. 
No noticeable difference was observed immediately after drug exposure (t = 0 h) between the 
anthraquinone-treated cells and the non-treated controls (results not shown). However, a 
significant effect was observed after 24 and 48 h recovery time, with cells primarily arrested 
in G2 (Figure 4). Alchemix appeared to induce a significant accumulation of cells in G1 phase 
(51.8% versus 35.5% of control cells) after 3 h recovery, which was not evident with the other 
anthraquinones.  
        
 
Figure 4 
 
 
3.6. Cell death pathways 
The induction of apoptosis and necrosis following the exposure of HCT116p53+/+ cells to 
alchemix and the three derivatives is presented in Figures 5 and 6. Cells were exposed to 
compounds at IC80 for 1 h and after washing cells were incubated in drug-free medium for 24 
h before assessing the level of apoptotic and necrotic cells. A SAR between the length of the 
hydrocarbon linker and number of apoptotic and necrotic cells was observed for the three 
derivatives. ICT2903, the compound with the longest linker (pentyl) induced the highest level 
Page 15 of 31 
 
of apoptotic (9.4 ± 1.6 %) and necrotic (9.3 ± 2.6) cells. Intriguingly, alchemix was found 
outside this SAR, exhibiting the highest level of apoptotic cells (10.1 ± 0.2 %) of all four 
compounds.  
 
 
 
 
 
 
Figure 5 
 
 
 
Figure 6 
 
 
 
3.7. γH2AX phosphorylation  
HCT116p53+/+ cells were used to evaluate the ability of the anthraquinones to induce DSBs. 
The HCT116 cells were exposed to anthraquinone concentrations equal to IC80 for 1 h, 
followed by a recovery period in fresh medium for 3, 24 or 48 h. A time-dependent increase 
in γH2AX phosphorylation was observed for all compounds bar ICT2901, which 
demonstrated noticeable activation after only 3 h (Figure 7).  
 
Figure 7 
 
 
 
3.8. Repair of DNA adducts in CHO cell lines 
To establish the roles of DNA repair mechanisms in repairing adducts generated by the 
anthraquinones, a panel of Chinese hamster ovary (CHO) cell lines, with specific defects in 
DNA excision repair was employed. The sensitivity of the CHO cells to the anthraquinones 
was assessed using the DRAG assay [20]. Table 4 shows the sensitivity of the wild-type 
(AA8) and the DNA-defective repair CHO cell lines mutants to the respective anthraquinones 
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after 120 h exposure to increasing concentrations of the agent. Increased sensitivity for the 
three compounds tested (alchemix, ICT2901 and ICT2903) was observed in the UV4 cell line, 
which harbors a defect in the ERCC1 gene known to affect nucleotide excision repair (NER) 
repair pathways. In addition, alchemix was slightly more cytotoxic to cells defective in 
ERCC2 (2.1 fold) and XRCC1 (1.2 fold), which may be indicative of failure to repair 
transcription-coupled nucleotide excision repair and base excision repair (BER) respectively.  
 
 
Table 4 
 
 
4. Discussion 
Alchemix is the prototype of a class of anthraquinone derivatives with a dual mode of action 
that combines DNA intercalating and alkylating properties. Alchemix has previously been 
shown to exhibit significant growth delay against anthracycline- and cisplatin-resistant 
xenografts [15]. This activity is derived from DNA intercalation, mono-alkylation and 
inhibition of topo IIα without inter-strand DNA cross-linking [13, 15]. Furthermore, unlike a 
classical topo IIα inhibitor such as doxorubicin, alchemix is neither a substrate for P-gp [15, 
23] nor significantly affected by the lower levels of topo IIα present in resistant A2780/adr 
cells [24]. This study examined the nature of DNA binding by alchemix and subsequent 
cellular pharmacology. To that effect three novel analogues were designed to aid the 
interpretation of not only the DNA binding data, but also provide insights into how DNA 
injury may be recognized and cause downstream activation of cell death pathways. 
 The results presented in this report suggest that subtle modification to the sidechain 
carrying the alkylating group of alchemix has a profound effect on DNA binding. The four 
anthraquinones were assessed for DNA binding by measuring their induced effects on the UV 
thermal melting profiles (∆Tm) of duplex-form CT DNA. All compounds were found to shift 
the DNA melting curve moderately at t = 0, however notable differences in the stabilization of 
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the DNA duplex were evident when studied over longer incubation times (Table 1). Alchemix 
(ethyl) and ICT2901 (propyl) exhibited the greatest stabilizing effect on DNA and the most 
persistent adducts, showing only a slight decrease in ∆Tm over 24 h. In contrast, the 
compounds with longer sidechains, ICT2902 (butyl) and ICT2903 (pentyl), were less 
effective DNA stabilants and over the course of 24 h incubation, ∆Tm decreased to zero. 
Drugs derived from the nitrogen mustard family are known to generate purine-sugar 
glycosidic linkages that become labile and prone to depurination over long exposure times or 
elevated temperatures [25]. Accordingly, it is possible that the longer and more flexible 
alkylating sidechains of ICT2902 and ICT2903 are responsible for achieving a higher number 
of G(N7) mono-adducts that are prone to depurination. Indeed, ICT2902 and ICT2903 were 
the most potent agents in the Taq polymerase footprinting assay, showing detectable DNA 
alkylation at 5 nM but still without the capacity to inter-strand cross-link DNA. ICT2903, 
alkylated all the guanines in the guanine-rich sequence 5'-GGGGG (bp = 536-540) and 
showed a modest preference for the 5'-peripheral guanines. In contrast, the nitrogen mustard, 
at ~200-fold higher dose, showed a preference for alkylating the central guanines in this 
sequence of contiguous guanines. This selectivity is due to enhanced nucleophilicity of the 
G(N7) nucleophiles in this sequence and is shared by many low molecular weight 
electrophilic drugs [21]. As such, it is apparent that the alkylation sites of mechlorethamine 
were modulated by tethering the bis-chloroethylamino moiety to the anthraquinone 
pharmacophore, indicating that the latter directed the site of covalent bonding. The higher 
potency of G alkylation by the butyl and pentyl linker compounds, suggests an improved 
compliance with the stereoelectronic requirements of the alkylation reaction. Despite of the 
higher potency in alkylating DNA, no correlation to cellular potency was apparent. Taken 
together, the results suggest that alchemix and ICT2901 with the shorter sidechains are able to 
bind to DNA in such a way that a stable DNA-drug non-covalent complex is obtained.  
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 The anthraquinones showed dose-dependent anti-proliferative activity with IC50<100 
nM (Tables 2 and 3) against both sensitive and resistant HCT116 and MCF-7 human cancer 
cells. Generally, the anthraquinones were equitoxic after both short-term (1 h) and long-term 
(96 h) exposure. In contrast, doxorubicin was less active at 1 h than after 96 h in the MCF-7 
cell line (≈35-fold) and the doxorubicin-resistant sub-line MCF-7/adr (≈10-fold), suggesting 
that the more lipophilic nature of the anthraquinones allows them to be taken up in the cells 
more readily than the more hydrophilic anthracycline. Significantly, after 96 h exposure, the 
MCF-7/adr cell line that expresses the MDR-1 phenotype was 1.6- and 4.6-fold more 
sensitive to alchemix and ICT2901 respectively compared with wild-type MCF-7 cells. In 
contrast to ICT2902 and ICT2903, alchemix and ICT2901 formed stable complexes with 
DNA (Table 1), however they were shown to be less potent topo IIα inhibitors. The MCF-
7/adr cell line has been shown to possess a reduction in topo IIα protein compared to the 
MCF-7 cell line [26], which support why loss of activity of the two most potent topo IIα 
inhibitors ICT2902 and ICT2903 is observed.  
 The tumor suppressor p53 plays a central role in integrating various stress signals, in 
particular genotoxic stresses such as DNA damage, hypoxia, and oncogene activation [10, 27, 
28]. It is mutated in more than 50% of human cancers [28] and has been shown to cause 
resistance to chemotherapy [29]. Accordingly, the development of drugs that act 
independently of p53 or even exploit defective p53 as a means of preferential toxicity is very 
important [29, 30]. The anthraquinones investigated herein are relatively unaffected by the 
p53 status of colorectal HCT116 cells, as only 1.5–3-fold loss of cytotoxicity was observed in 
the p53-null cells after 96 h. In addition, the MCF-7/adr cell line, that harbors a mutation in 
p53 [31], demonstrated slightly increased sensitivity to alchemix and ICT2901. Overall 
results from the four cell lines investigated indicate that p53 plays a negligible part in 
mediating the cytotoxicity of these two agents.  
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 DNA damage is known to elicit a multifaceted cellular response that includes 
activation of DNA repair pathways, cell cycle checkpoints, and programmed cell death [30]. 
The latter may occur by several molecular mechanisms [32]. Apoptosis is one of the 
mechanisms by which chemotherapeutic agents might induce cancer cell demise [33]. There 
is increasing evidence that an inability to engage apoptosis can represent a resistance 
mechanism to cytotoxic drugs [34]. In regard to alchemix and the three analogues, it was 
desirable to investigate whether their cytotoxic potency was linked with apoptosis and/or 
necrosis. Data obtained from our studies appeared to show an SAR between increase in 
sidechain length of the three novel compounds (ICT2901–3), potency in DNA alkylation and 
increase in number of apoptotic and necrotic cells after short term (1 h) drug exposure. 
Interestingly, alchemix was found to be outside this SAR, implying differences in its 
mechanism of action. Early analysis (3 h) of cell cycle phase perturbations may also suggest a 
difference in mechanism of action as a higher number of G1 cells appeared to be arrested by 
alchemix treatment. This ability to perturb cells in G1 phase cells in the early stages after drug 
treatment may add significantly to the overall efficacy of alchemix.  
 DNA double strand breaks (DSBs) or damage at replication forks can be detected by 
phosphorylation of histone 2AX variant to form  γH2AX focus formation. The role of γH2AX 
is to recruit DNA repair and cell cycle checkpoint proteins required for the efficient 
processing of DNA lesions [35]. All four compounds investigated in this study caused 
γH2AX phosphorylation after longer recovery times (24 h and 48 h). Intriguingly, significant 
γH2AX phosphorylation after short-term exposure (3 h) was only observed for ICT2901. As 
DNA interstrand crosslinking with naked DNA did not occur (supporting information, Figure 
S1), it is possible that the ICT2901-induced DNA damage and subsequent γH2AX 
phosphorylation arise after processing or signaling DNA damage.  
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 In support for the adduct formation we observed that alchemix, ICT2901 and ICT2903 
are all potentiated in the absence of the excision repair gene ERCC1, which is involved in 
NER, homologous recombination and inter-strand crosslink repair [36]. The UV5 cell line is 
defective in the XPD protein, which is involved in NER and crosslink repair [37], but not 
homologous recombination [38]. Since only the UV4 and not the UV5 cell line was sensitive 
to ICT2901 and ICT2903, it implicates that homologous recombination is involved in the 
response to these agents. Indeed, the irs1SF and NM3 cell lines defective in the recombination 
proteins XRCC3 and XRCC9 (FANCG) were both highly resistant to ICT2901 and ICT2903. 
This is in sharp contrast to the sensitivity of these cells to crosslinking agents and topo II 
inhibitors [39, 40]. These data demonstrate a separation of function between commonly used 
anti-cancer treatments and ICT2901 and ICT2903. Furthermore, it demonstrates that the 
proteins involved early in homologous recombination (XRCC3, FANCG) are required to 
mediate the toxicity, while proteins involved late in homologous recombination (ERCC1) are 
required for survival. These data point to that a recombination intermediate is mediating the 
toxicity, especially of ICT2901 and ICT2903, but likely also alchemix. Furthermore, 
alchemix has a different toxicity pattern to the DNA repair defective cell lines as compared to 
ICT2901 and ICT2903, demonstrating that it has a distinct mode of action. Since UV5 cells 
are sensitive to alchemix, we speculate that alchemix forms, in addition to a lesion similar to 
ICT2901 and ICT2903, also a DNA adduct repaired by NER. Mechanistically, we speculate 
that repair is initiated at the DNA adduct site to create a toxic lesion and that the intercalating 
part of the molecule interfere with proteins involved in the completion of recombination 
repair.  
 In summary, we have shown that subtle synthetic modifications to alchemix lead to 
significant changes in stability of DNA adducts and cellular pharmacology. The standard 
treatment for many solid and hematological cancers, despite limitations with regard to MDR, 
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is still based on cytotoxics such as the anthraquinone-based drugs doxorubicin or 
mitoxantrone. Despite the identification of cancer-specific molecular targets and the 
significant advances in a new generation of less toxic therapeutics the urgent need to treat 
relapsed patients with drug-resistant tumours remains. In this context, agents such as alchemix 
or ICT2901, that evade multiple resistance mechanisms, may provide an attractive solution to 
this unmet clinical need. 
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Table Legends 
 
Table 1 Thermal denaturation of CT-DNA in the presence of the four alkylating agents 
 
Below the Table: a Anthraquinones were subjected to DNA thermal melting (denaturation) 
studies using CT-DNA at a fixed 5:1 (50 µM DNA:10 µM compound) ratio. The DNA-
anthraquinone mixtures were incubated at 37 °C and evaluated at 0, 4, 8 and 24 h. Results for 
each compound are from three separate determinations with mean Tm values ± 0.1 ºC. See 
materials and methods for details. 
 
Table 2 Growth Inhibition of Alkylating Anthraquinones against Wild-Type and p53 Null 
HCT116 Carcinoma Cell Lines 
 
Below the Table: All IC50 values are in nM and the data represent the means of three 
independent experiments ± SD. RF = resistance factor (IC50 in resistant cell line/IC50 in parent 
cell line).  
 
Table 3 Growth Inhibition of Alkylating Anthraquinones against MCF-7 and MCF-7/adr 
Carcinoma Cell Lines 
 
Below the Table: All IC50 values are in nM except where indicated for doxorubicin.  The data 
represent the means of three independent experiments ± SD. RF = resistance factor (IC50 in 
resistant cell line/IC50 in parent cell line).  
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Table 4 Growth Inhibition of Alkylating Anthraquinones against A Panel of CHO Cell Lines 
with Gene Defects  
 
Below the Table: The data represent the means of two independent experiments ± SD after 
treatments with indicated compounds. SR = sensitivity factor (IC50 in parent cell line/IC50 in 
defective cell line).  
 
Figure Legends 
 
Fig. 1 Alkylating anthraquinones 
 
Fig. 2 Effects of alchemix, ICT2901, ICT2902, and ICT2903 on Taq DNA polymerase 
elongation of plasmid pBR322. Control: unmodified DNA; The solid triangles represent 
increasing of compounds; from left to right, these are: 1, 2.5, 10 µM for HN2 
(mechlorethamine) and 1, 5, 25, 100 nM for anthraquinones. 
 
Fig. 3 Effects of the indicated compounds on decatenation of kinetoplast DNA in the presence 
of topo IIα. Each compound was tested at 1 µM (A) and 0.1 µM (B).   
 
Fig. 4 Anthraquinone-induced changes in the cell cycle phase distribution. Parental 
HCT116p53+/+ cells were treated with the indicated drug at IC80 (alchemix = 188 nM, ICT2901 
= 100 nM, ICT2902 = 177 nM and ICT2903 = 339 nM) for 1 h followed by a 3, 24, 48 h 
incubation in anthraquinone-free medium. The cell cycle distribution was determined by 
propidium iodide staining and flow cytometry. The data are normalized to control untreated 
Page 26 of 31 
 
cells and presented as fold change (represented by the broken line) from three independent 
experiments.  
 
Fig. 5 Anthraquinone-induced apoptotic cell death. Parental HCT116p53+/+ cells were treated 
with the indicated compound at IC80 (alchemix = 188 nM, ICT2901 = 100 nM, ICT2902 = 
177 nM and ICT2903 = 339 nM) for 1 h followed by 24 h incubation in anthraquinone-free 
medium. Cells were collected and analysed using the TUNEL assay. The treated cells (grey 
bars) and control cells (white bars) represent the means of three independent experiments ± 
SD.  
 
Fig. 6 Anthraquinone-induced necrotic cell death. Parental HCT116p53+/+ cells were treated 
with the indicated compound at IC80 (alchemix = 188 nM, ICT2901 = 100 nM, ICT2902 = 
177 nM and ICT2903 = 339 nM) for 1 h followed by 24 or 48 h incubation in anthraquinone-
free medium. Cells were collected and analysed using the Trypan Blue assay. The treated 
cells (grey bars) and control cells (white bars) represent the means of three independent 
experiments ± SD.  
 
Fig. 7 Anthraquinone-induced changes in γH2AX foci. Parental HCT116p53+/+ cells were 
treated with the indicated compound at IC80 (alchemix = 188 nM, ICT2901 = 100 nM, 
ICT2902 = 177 nM and ICT2903 = 339 nM) for 1 h followed by a 3, 24, 48 h incubation in 
anthraquinone-free medium. Cells were then stained with Phospho-Histone H2AX (Ser139) 
antibody as described in materials and methods. The treated cells (black bars) and control 
cells (grey bars) represent the means of three independent experiments ± SD.  
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Table 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 
 
 
 
 
 
 
 
 
 
 
Table 3 
 
 
Table 4 
 
Cell line Gene defect Alchemix ICT2901 ICT2903 IC50 [nM] SR IC50 [nM] SR IC50 [µM] SR 
AA8  42.9 ± 6.8  11.5 ± 5.0  0.2 ± 0.0  
UV4 ERCC1 13.3 ± 1.4 3.2 6.0 ± 4.5 1.9 0.1 ± 0.0 1.3 
UV5 ERCC2 20.8 ± 1.2 2.1 15.4 ± 12.6 0.7 0.2 ± 0.0 0.8 
EM9 XRCC1 36.4 ± 12.5 1.2 12.8 ± 10.1 0.9 0.4 ± 0.2 0.5 
irs1SF XRCC3 100.9 ± 46.4 0.4 35.9 ± 32.9 0.3 7.0 ± 1.6 0.0 
NM3 XRCC9 65.4± 72.6 0.7 144.8 ± 141.9 0.1 8.6 ± 1.1 0.0 
V3-3 XRCC7 92.9 ± 21.6 0.5 34.2 ± 29.2 0.3 0.6 ± 0.0 0.3 
 
 
 
 Induced ∆Tm (°C)a 
Compound 0 h 4 h 8 h 24 h 
Alchemix 11.0 11.0 10.9 9.5 
ICT2901 14.8 14.9 14.8 13.6 
ICT2902 7.0 4.8 4.7 1.3 
ICT2903 6.5 3.6 3.2 -0.8 
 1 hour 96 hours 
Compound p53+/+ p53-/- RF p53+/+ p53-/- RF 
Alchemix 48 ± 13  53.5 ± 20 1.1 28.5 ± 5.6 45 ± 11 1.6 
ICT2901 14 ± 4.7  23 ± 13 1.7 13.3 ± 3.3 43 ± 13 3.3 
ICT2902 34 ± 16 52  ± 39 1.6 26 ± 10. 55 ± 16.5 2.1 
ICT2903 76 ± 17  98 ± 29 1.3 66.8 ± 7.2 91 ± 44 1.4 
 1 hour 96 hours 
Compound MCF-7 MCF-7/adr RF MCF-7 MCF-7/adr RF 
Alchemix 85 ± 36 73 ± 16.  0.85 48 ± 10 28.6 ± 8.8 0.6 
ICT2901 15.5 ± 6.9 5.3 ± 0.9 0.34 13.5 ± 6.4 2.9 ± 0.8 0.2 
ICT2902 26 ± 14 37.25 ± 0.78 1.5 36.3 ± 4.1 52.5 ± 17.7 1.4 
ICT2903 91 ± 24  314 ± 1295  3.5 92 ± 28 320 ± 99 3.5 
Doxorubicin 6.1 ± 1.7 µM > 100 µM > 17 218 ± 91 > 10 µM > 45 
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Figure 4 
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